Outcomes of the 30-mg group versus the > 30-mg group
| . | > 30 mg (n = 53) . | 30 mg (n = 28) . | P . |
|---|---|---|---|
| Graft-versus-host disease | |||
| Grade II-IV aGVHD events (%) | 3 (6) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | 0.91 (0.1-10.0) | |
| Grade III-IV aGVHD events (%) | 0 (0) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | NA | |
| Extensive cGVHD events | 6 (11) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | 0.2 (0.03-1.71) | |
| Grade III-IV/ext cGVHD events (%) | 6 (11) | 2 (7) | NS |
| HR (95% CI) | 1 (ref) | 0.4 (0.1-2.2) | |
| Non-relapse mortality | |||
| 100 d, % (95% CI) | 4 (1-11) | 0 (0-0) | NS |
| 1 y, % (95% CI) | 11 (5-21) | 7 (1-20) | NS |
| 2 y, % (95% CI) | 20 (10-31) | 7 (1-20) | NS |
| Progression-free survival | |||
| 2 y, % (95% CI) | 71 (51-85) | 71 (51-85) | NS |
| Overall survival | |||
| 2 y, % (95% CI) | 69 (54-80) | 82 (62-92) | NS |
| Full donor chimerism (%) | |||
| 3 mo | 42 | 36 | NS |
| 2 y | 81 | 64 | NS |
| Infections | |||
| Total, median/patient (IQR) | 3 (1-4) | 2 (1-4) | NS |
| CMV reactivation, % | 77 | 83 | NS |
| CMV disease, % | 13 | 6 | NS |
| Median lymphocyte count, ×109/L (IQR) | |||
| 1 mo | 0.1 (0.1-0.4) | 0.2 (0.1-0.3) | NS |
| 3 mo | 0.9 (0.4-1.3) | 0.8 (0.4-1.9) | NS |
| 6 mo | 1.1 (0.6-1.5) | 0.9 (0.7-2.0) | NS |
| 12 mo | 1.2 (0.8-1.7) | 1.7 (1.1-2.5) | .01 |
| . | > 30 mg (n = 53) . | 30 mg (n = 28) . | P . |
|---|---|---|---|
| Graft-versus-host disease | |||
| Grade II-IV aGVHD events (%) | 3 (6) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | 0.91 (0.1-10.0) | |
| Grade III-IV aGVHD events (%) | 0 (0) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | NA | |
| Extensive cGVHD events | 6 (11) | 1 (4) | NS |
| HR (95% CI) | 1 (ref) | 0.2 (0.03-1.71) | |
| Grade III-IV/ext cGVHD events (%) | 6 (11) | 2 (7) | NS |
| HR (95% CI) | 1 (ref) | 0.4 (0.1-2.2) | |
| Non-relapse mortality | |||
| 100 d, % (95% CI) | 4 (1-11) | 0 (0-0) | NS |
| 1 y, % (95% CI) | 11 (5-21) | 7 (1-20) | NS |
| 2 y, % (95% CI) | 20 (10-31) | 7 (1-20) | NS |
| Progression-free survival | |||
| 2 y, % (95% CI) | 71 (51-85) | 71 (51-85) | NS |
| Overall survival | |||
| 2 y, % (95% CI) | 69 (54-80) | 82 (62-92) | NS |
| Full donor chimerism (%) | |||
| 3 mo | 42 | 36 | NS |
| 2 y | 81 | 64 | NS |
| Infections | |||
| Total, median/patient (IQR) | 3 (1-4) | 2 (1-4) | NS |
| CMV reactivation, % | 77 | 83 | NS |
| CMV disease, % | 13 | 6 | NS |
| Median lymphocyte count, ×109/L (IQR) | |||
| 1 mo | 0.1 (0.1-0.4) | 0.2 (0.1-0.3) | NS |
| 3 mo | 0.9 (0.4-1.3) | 0.8 (0.4-1.9) | NS |
| 6 mo | 1.1 (0.6-1.5) | 0.9 (0.7-2.0) | NS |
| 12 mo | 1.2 (0.8-1.7) | 1.7 (1.1-2.5) | .01 |
aGVHD indicates acute graft-versus-host disease; NS, not significant; HR, hazard ratio; CI, confidence interval; ref, reference; NA, not applicable; cGVHD, chronic graft-versus-host disease; IQR, interquartile range; and CMV, cytomegalovirus.